DCT and neoplasm: Furthermore, when combined with the use of the tyrosinase-related protein 2 (TRP2) tumor vaccine, M1-derived EVs can enhance the vaccine’s anti-tumor efficacy, as shown by higher killing capability, reduction in tumor size, the amount of apoptotic cells, and the histological images of tumors (Figure 5A) [132].